C
Christopher D. Davies
Researcher at AstraZeneca
Publications - 16
Citations - 363
Christopher D. Davies is an academic researcher from AstraZeneca. The author has contributed to research in topics: Acylation & Alkyl. The author has an hindex of 8, co-authored 16 publications receiving 317 citations. Previous affiliations of Christopher D. Davies include Cardiff University.
Papers
More filters
Journal ArticleDOI
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-Fluoro-2-Methylpropyl)-3-Methyl-2, 3,4,9-Tetrahydro-1H-Pyrido[3,4-B]Indol-1-Yl)Phenyl)Acrylic Acid (Azd9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
Chris De Savi,Robert Hugh Bradbury,Alfred A. Rabow,Richard A. Norman,Camila de Almeida,David M. Andrews,Peter Ballard,David Buttar,Rowena Callis,Gordon S. Currie,Jon Curwen,Christopher D. Davies,Craig S. Donald,Lyman Feron,H. Gingell,Steven C. Glossop,Barry R. Hayter,Syeed Hussain,Galith Karoutchi,Scott G. Lamont,Philip A. MacFaul,Thomas A. Moss,Stuart E. Pearson,Michael Tonge,Graeme Walker,Hazel M. Weir,Zena Wilson +26 more
TL;DR: The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described.
Journal ArticleDOI
Discovery, synthesis and biological evaluation of novel glucokinase activators.
Darren Mckerrecher,Joanne V. Allen,Suzanne S. Bowker,Scott Boyd,Peter William Rodney Caulkett,Gordon S. Currie,Christopher D. Davies,Mark L. Fenwick,Harold Gaskin,Emma Grange,Rod B. Hargreaves,Barry R. Hayter,Roger James,Keith M. Johnson,Craig Johnstone,Clifford David Jones,Sarah Lackie,Rayner John Wall,Rolf Peter Walker +18 more
TL;DR: The identification, synthesis and SAR of a novel series of glucokinase activators is described, and compound 22 highlighted as having a suitable balance between lipophilicity, potency and physical properties.
Patent
Quinoline derivatives as glucokinase ligands
TL;DR: In this paper, one of R1 and R2 is selected from a group (IA), ring A is a substituted pyridin-zyl of thiazol-z-yl, the other substituents are as described in the description and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase.
Journal ArticleDOI
Synthesis and stereochemical determination of batzelladine C methyl ester
Michael Butters,Christopher D. Davies,Mark Christopher Elliott,Joseph T. Hill-Cousins,Benson M. Kariuki,Liling Ooi,John L. Wood,Stuart V. Wordingham +7 more
TL;DR: The two possible diastereoisomers of the methyl ester corresponding to this compound have been synthesised, permitting the relative and absolute stereochemistry of this compound to be assigned.
Journal ArticleDOI
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.
Chris De Savi,Andrew Pape,John G. Cumming,Attilla Ting,Peter D. Smith,Jeremy N. Burrows,Mark Mills,Christopher D. Davies,Scott G. Lamont,David Milne,Calum Cook,Peter R. Moore,Yvonne Sawyer,Stefan Gerhardt +13 more
TL;DR: Two series of N-hydroxyformamide inhibitors of ADAM-TS4 were identified from screening compounds previously synthesised as inhibitors of matrix metalloproteinase-13 (collagenase-3), finding potent and very selective inhibitors with favourable DMPK properties.